Jiang Run-Song, Zhao Zheng-Yan
Department of Reconstructive Plastic Surgery, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Oncol Lett. 2017 Jun;13(6):4887-4891. doi: 10.3892/ol.2017.6064. Epub 2017 Apr 20.
Kasabach-Merritt syndrome (KMS) is a rare type of vascular tumor associated with a severely decreased platelet count. No standard guidelines for the treatment of the disease have been established so far. In the present study, a 1-year-old pediatric patient with KMS arising from tufted angioma was successfully and variously treated with steroids, vincristine, surgery and propranolol for 18 months. Systemic steroids stabilized the platelet count stable, while vincristine reduced the size of the tumor. Due to unpredictable response, the patient was operated. Combination of vincristine and propranolol was introduced post-surgery to improve the severely low platelet count of the patient. Following multimodal therapy for 18 months, there has been no evidence of recurrence or metastasis during 2 years of follow-up. Currently, the patient is alive and well. The management of KMS presents a challenge, and well-designed studies are required to clearly determine the benefits and risks of multidisciplinary treatment.
卡萨巴赫-梅里特综合征(KMS)是一种罕见的血管肿瘤,伴有血小板计数严重降低。目前尚未制定出该疾病的标准治疗指南。在本研究中,一名1岁患有丛状血管瘤引发KMS的儿科患者,接受了类固醇、长春新碱、手术和普萘洛尔治疗,历时18个月,治疗取得成功且方式多样。全身性类固醇使血小板计数保持稳定,而长春新碱缩小了肿瘤大小。由于反应不可预测,对该患者实施了手术。术后采用长春新碱和普萘洛尔联合治疗,以改善患者严重偏低的血小板计数。经过18个月的多模式治疗,在2年的随访期间未发现复发或转移迹象。目前,该患者存活且状况良好。KMS的治疗颇具挑战性,需要精心设计的研究来明确多学科治疗的益处和风险。